GuatemalaTuberculosis profile
Population  2014 16 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.26 (0.24–0.28) 1.6 (1.5–1.7)
Mortality (HIV+TB only) 0.54 (0.46–0.63) 3.4 (2.9–3.9)
Prevalence  (includes HIV+TB) 17 (8.6–28) 106 (54–176)
Incidence  (includes HIV+TB) 9.2 (8.1–10) 57 (51–64)
Incidence (HIV+TB only) 0.84 (0.7–1) 5.3 (4.3–6.3)
         
Case detection, all forms (%) 34 (31–39)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 3 (1.8–4.6) 26 (20–34)
MDR-TB cases among notified pulmonary
TB cases
79 (49–120) 55 (41–71)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 2 103   132
Pulmonary, clinically diagnosed 550   15
Extrapulmonary 352   11
       
Total new and relapse 3 163    
Previously treated, excluding relapses 61    
Total cases notified 3 224    
Among 3 163 new and relapse cases:
284 (9%) cases aged under 15 years; male:female ratio: 1.3
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 353 (17%) 151 (69%) 381
Laboratory-confirmed RR-/MDR-TB cases     62
Patients started on MDR-TB treatment ***     42
TB/HIV 2014 Number (%)
TB patients with known HIV status 2 782 (86)
HIV-positive TB patients 245 (9)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 228 (93)
HIV-positive TB patients on antiretroviral therapy (ART) 228 (93)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (84) 2 978
Previously treated cases registered in 2013 (67) 36
HIV-positive TB cases, all types, registered in 2013 (62) 243
RR-/MDR-TB cases started on second-line treatment in 2012 (69) 39
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 1.8
Culture (per 5 million population) 3.1
Drug susceptibility testing (per 5 million population) 0.9
Sites performing Xpert MTB/RIF 11
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 11
% Funded domestically 88%
% Funded internationally 6%
% Unfunded 7%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-07-27 Data: www.who.int/tb/data